Brand Reference: Robinul
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) RxNorm Concept ID | 4917 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1650 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $62.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $8.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $11.00 / mo | 26 Zero-PHI Verified Patient Logs |
Permanently positively charged quaternary ammonium structure cannot cross the lipid blood-brain barrier (preventing oxybutynin-associated dementia/cognitive fog), selectively blocking peripheral cholinergic M3 receptors on eccrine sweat glands in primary craniofacial/palmar hyperhidrosis.
Across 26 community cost disclosures for Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) (Robinul), cash buyers routing around $62.00 retail markups capture a 86% discount ($8.90/mo benchmark vs $0.1650 NADAC acquisition).
Following administration (1 mg PO fasting QAM), Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) achieves ~5%–10% fasting oral (high-fat food cuts absorption by 75%—MUST take 2h fasting!) bioavailability and 60–90 minutes fasting onset, governed by a 0.8–3 hours plasma / 8–10 hours eccrine anhidrotic duration terminal half-life through 85% excreted unchanged in bile and urine.
Before initiating Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) at 1 mg PO fasting QAM, clinical safety checklists rule out narrow-angle glaucoma; myasthenia gravis; paralytic ileus or obstructive bph. Logged tolerability patterns center on dry mouth (dose-titratable) (48% of reports), dry eyes (16% of reports).
Across 26 verified cash-pay logs, Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) achieves a 92.30% Worth-It rating with out-of-pocket spend averaging $11.00/mo versus $62.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 1 mg PO fasting QAM for Glycopyrrolate (Quaternary Non-CNS Antimuscarinic); monthly out-of-pocket dropped to $7.83 compared with $62.00 retail.
Completed 10 weeks on Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) (2 mg PO fasting QAM (may add 1 mg midday)). Zero notable side effects on steady dosing.
Consistent biomarker response on 1 mg PO fasting QAM Glycopyrrolate (Quaternary Non-CNS Antimuscarinic) sourced via Compounding ($10.32/mo cash pay without insurance prior authorization).